Search

In a world being urged to embrace renewable options, biodiesel fuels are increasingly being touted as a greener, cleaner choice than traditional diesel.

News & Events

Perth researchers have found toxic and harmful chemicals in several dozen e-cigarette liquids readily available in Australia.

News & Events

A $350,000 Cure4 Cystic Fibrosis grant is set to propel the Wal-yan Respiratory Research Centre’s Phage WA program forward, supercharging its fight against antimicrobial resistant (AMR) lung infections in people with Cystic Fibrosis (CF) using  cutting-edge phage therapy.

News & Events

Preterm researchers Dr Shannon Simpson (left) and Professor Jane Pillow (right) with Tony Sparks WA chairperson Amber Bates.

News & Events

The AERIAL study, in partnership with The ORIGINS Project, endeavours to understand if exposures during pregnancy and early life can affect the cells lining the airways in newborns, and whether this is associated with the development of wheeze, allergy and asthma later in childhood.

News & Events

Patients battling antibiotic-resistant superbugs will soon have access to life-saving WA-made therapies that could help treat lung, skin and ear infections as well as bacterial infections like Golden Staph. Western Australia's inaugural phage manufacturing facility – spearheaded by a team at the

Research

The European Respiratory Society Oscillometry Taskforce identified that clinical correlates of bronchodilator responses are needed to advance oscillometry in clinical practice. The understanding of bronchodilator-induced oscillometry changes in preterm lung disease is poor. Here we describe a comparison of bronchodilator assessments performed using oscillometry and spirometry in a population born very preterm and explore the relationship between bronchodilator-induced changes in respiratory function and clinical outcomes.

Research

Pulmonary bacterial infections present a significant health risk to those with chronic respiratory diseases including cystic fibrosis and chronic-obstructive pulmonary disease. With the emergence of antimicrobial resistance, novel therapeutics are desperately needed to combat the emergence of resistant superbugs.

Research

Bronchiectasis is a worldwide chronic lung disorder where exacerbations are common. It affects people of all ages, but especially Indigenous populations in high-income nations. Despite being a major contributor to chronic lung disease, there are no licensed therapies for bronchiectasis and there remain relatively few randomised controlled trials (RCTs) conducted in children and adults.

Research

Improvements in neonatal critical care have resulted in more people than ever reaching adulthood after being born prematurely. At the same time, it is becoming clearer that preterm birth can increase the risk of respiratory disease throughout a person’s lifetime. Awareness that a patient was born preterm can enable early specialist assessment and intervention when there is any concern about lung health.